SCHEMBL6174389

SCHEMBL6174389

Cc1ccc2nccc(CC3(C)NC(=O)N(c4ccc(SC(F)(F)F)cc4)C3=O)c2c1

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 19/20 0.42
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173427 0.89 IGF1R (0.45) IGF1R
SCHEMBL6175028 0.89 IGF1R (0.45) IGF1R
SCHEMBL6172290 0.89 IGF1R (0.45) IGF1RSMN1; SMN2
SCHEMBL6174899 0.89 IGF1R (0.45) IGF1RSMN1; SMN2
SCHEMBL6173605 0.86 IGF1R (0.45) IGF1R
SCHEMBL6174285 0.85 IGF1R (0.46) IGF1R
Trifluoroacetic Acid SCHEMBL17558379 0.85 IGF1R (0.42) IGF1R
SCHEMBL6175587 0.84 IGF1R (0.45) IGF1R
SCHEMBL6174914 0.82 IGF1R (0.40) IGF1R
SCHEMBL6176318 0.80 IGF1R (0.42) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed